Research and Markets: Biosimilars: A Physician's Perspective

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/55d346/biosimilars_a_phy) has announced the addition of the "Biosimilars: A Physician's Perspective" report to their offering.

To say the environment around biosimilars is fluid would be an understatement. With fluidity comes uncertainty and with uncertainly comes opportunity. Many industry pundits are evaluating the biosimilar market by taking a big picture, macro assessment of the regulatory, clinical development, and commercialization issues. Industry Standard Research (ISR) took a focused approach to answering a few pointed questions around the potential prescribing of biosimilars. The publisher took this approach because of the fluid nature of the environment and because regardless of the nascent legislation recently enacted in the United States, or the forthcoming plan from the FDA, and the relative low adoption of biosimilars in Europe; they believe that physicians/prescribers will be at the strategic center of biosimilar success or failure.

Key Topics Covered:

  • Clinical trial expectations
  • Price expectations
  • Adoption expectations
  • Safety and Efficacy expectations from Innovator and Generic manufacturers

For more information visit http://www.researchandmarkets.com/research/55d346/biosimilars_a_phy



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

GigaGen reported that its antibody treatment against COVID-19 was 100 times more protective than plasma and could be ready for human trials in 2021.

Seres Therapeutics is looking for a speedy approval of its once failed drug after it comes through a phase 3 test.